Market Shifts Make Mylan’s Perrigo Gambit More ‘Questionable’
This article was originally published in The Tan Sheet
Executive Summary
Perrigo’s Rx generic topicals growth could slow as more competition likely will launch earlier than excepted and its royalties from a drug indicated for multiple sclerosis could slow sooner than expected as other pharmas developing similar drugs reach pipeline milestones early, Bernstein analyst Ronny Gal comments.